ArticlePloS one2026
A novel mRNA-based multiepitope vaccine candidate against Cryptosporidium hominis and Cryptosporidium parvum employing reverse-vaccinology and immunoinformatics approaches.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe parasite Cryptosporidium spp. causes cryptosporidiosis, a diarrheal disease in humans and animals. This study describes the development of mRNA vaccine targeting antigens from C. hominis and C. parvum, important gut pathogens. This vaccine was designed with reverse vaccinology and immunoinformatics as no FDA-approved vaccine exists for cryptosporidiosis. MATERIALS AND
methodsInitially, a thorough literature review was conducted to identify five pathogenic proteins (aminopeptidase, heat shock protein, P23, serine protease, and sporozoite glycoproteins) associated with these two parasites. Next, a multiple sequence alignment was conducted, and the conserved sequences were used to design a novel multiepitope mRNA vaccine against these two parasites, combining the best CD8+, CD4+, and continuous B-cell epitopes. Additionally, structural prediction, docking, dynamics, and immune simulation, as well as cloning, were conducted.
resultThe vaccine demonstrated standard biophysical properties, indicating that the protein is soluble and stable. Both two-dimensional (substantial alpha helix, beta sheet, and coil structures) and three-dimensional structures (Ramachandran score of 83.1% and a Z score of -7.39) of the vaccine were standard. The docking energy for TLR-2 (-1151.9) and TLR-4 (-1028.3) exhibited significant interactions. Furthermore, MM-GBSA and dynamics simulation both verified their stability, compactness, and flexibility. Next, codon optimization for Escherichia coli expression yielded promising results, with the vaccine demonstrating substantial expression, as evidenced by a GC content of 46.97% and a CAI of 0.988. Afterwards, immune simulation demonstrated robust immune response amplification upon repeated exposures. In addition, the vaccine exhibited stability in its mRNA structures.
conclusionThis study developed an in-silico multiepitope novel mRNA vaccine candidate for C. hominis and C. parvum with excellent structural stability, antigenicity, receptor-binding affinity, and expected immune responses. These findings offer a novel approach due to numerous species target but with significant drawbacks like no validation beyond simulation, uncertainty of long-term immunity, protein quality, stability and safety, requiring experimental validation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.